SCHEMBL662273

SCHEMBL662273

CCOC(=O)c1cccc(CCCOC)c1

nearest known ligand 0.74

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CYP4F2 P78329 3/20 0.74
CYP4A11 Q02928 3/20 0.74
MEP1B Q16820 1/20 0.51
NPC1 O15118 3/20 0.50
RAB9A P51151 3/20 0.50
MAPT P10636 2/20 0.50
PTGER4 P35408 2/20 0.50
SMN1; SMN2 Q16637 3/20 0.49
CYP1A2 P05177 1/20 0.49
CYP2C9 P11712 1/20 0.49
HPGD P15428 1/20 0.49
CYP2C19 P33261 1/20 0.49
CA2 P00918 1/20 0.48
LOXL2 Q9Y4K0 1/20 0.47
ALDH1A1 P00352 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10144991 0.91 CYP4F2 (0.69) CYP4F2CYP4A11MEP1BNPC1RAB9A
SCHEMBL1793142 0.87 CYP4F2 (0.81) CYP4F2CYP4A11MEP1BNPC1RAB9A
SCHEMBL8723505 0.86 CYP4F2 (0.74) CYP4F2CYP4A11MEP1BNPC1RAB9A
SCHEMBL8799839 0.85 CYP4F2 (1.00) CYP4F2CYP4A11MEP1BNPC1RAB9A
SCHEMBL28280189 0.84 CYP4F2 (0.76) CYP4F2CYP4A11MEP1BNPC1RAB9A
SCHEMBL20178551 0.84 CYP4F2 (0.76) CYP4F2CYP4A11MEP1BNPC1RAB9A
SCHEMBL11587961 0.84 CYP4F2 (0.76) CYP4F2CYP4A11MEP1BNPC1RAB9A
SCHEMBL17563119 0.84 CYP4F2 (0.76) CYP4F2CYP4A11MEP1BNPC1RAB9A
SCHEMBL12035616 0.83 CYP4F2 (0.75) CYP4F2CYP4A11MEP1BNPC1RAB9A
SCHEMBL13324061 0.83 CYP4F2 (0.74) CYP4F2CYP4A11MEP1BNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120046293-A1 RENIN INHIBITORS MERCK FROSST CANADA LTD. (CA) 2012-02-23 US disclosed
US-8063105-B2 Renin inhibitors MERCK CANADA INC. (CA) 2011-11-22 US disclosed
US-20090281103-A1 Renin Inhibitors MERCK CANADA INC. (CA) 2009-11-12 US disclosed
EP-1910272-A1 RENIN INHIBITORS Merck Frosst Canada Ltd. (CA) 2008-04-16 EP disclosed
WO-2007009250-A1 RENIN INHIBITORS MERCK FROSST CANADA LTD. (CA) 2007-01-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120046293-A1 RENIN INHIBITORS REN, ACE, AGTR1 CYP4F2 562/4885CYP4A11 231/4885MEP1B 2305/4885
US-20090281103-A1 Renin Inhibitors REN, ACE, AGT CYP4F2 257/4885CYP4A11 53/4885MEP1B 1045/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.